Takeda Oncology
Tom Spalding is an accomplished leader in the oncology field, currently serving as the Head of Global Oncology Products, Pipeline and Strategy at Takeda Oncology since November 2024, overseeing Global Marketing and Operations. Prior to this role, Tom held various senior positions at AbbVie, including Vice President of Oncology for Global Marketing and Commercial Operations, and Vice President of Oncology, Pipeline Commercial Strategy, focusing on Business Development and Commercial Assessments. Tom's extensive experience also includes serving as Chief Commercial Officer at Caris Life Sciences, Worldwide Vice President at Johnson & Johnson in Molecular Diagnostics, and various roles at The Janssen Pharmaceutical Companies of Johnson & Johnson. Tom holds an MBA in Finance/Marketing from Boston College and a BA in Pre-Med/English from the College of the Holy Cross.
This person is not in any teams
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.